Results 191 to 200 of about 104,817 (211)

A randomized, double-blind, placebo-controlled trial of olanzapine versus placebo plus ondansetron and dexamethasone for antiemetic prophylaxis in patients receiving oxaliplatin-, irinotecan-, or carboplatin-based chemotherapy. [PDF]

Support Care Cancer
Harikul W, Nimmannit A, Laocharoenkeat A, Phisalprapa P, Kositamongkol C, Thongkijpreecha P, Ithimakin S.   +6 more
europepmc   +1 more source

Cost-effectiveness of switching to S-1 after fluoropyrimidine-induced hand-foot syndrome or cardiovascular toxicity in the treatment of metastatic colorectal cancer. [PDF]

ESMO Open
van Eekelen R, Punt CJA, Kwakman JJM, Coupé VMH.   +3 more
europepmc   +1 more source

OSBPL3-driven sterol metabolic reprogramming promotes oncogenic signaling and therapeutic resistance in pancreatic cancer. [PDF]

Theranostics
Sun Q, Li X, Zou Q, Chen Y, Zhu X, Jiang H, Jiang T, Wei F, Xie K.   +8 more
europepmc   +1 more source

Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer. [PDF]

Br J Cancer
Ree AH, Bousquet PA, Visnovska T, Lüders T, Geisler BP, Wang S, Bordin DL, Nilsen HL, Hamre HM, Kersten C, Hofsli E, Guren MG, Sorbye H, Berg JP, Flatmark K, Meltzer S.   +15 more
europepmc   +1 more source

A Successful Rechallenge in a Patient With Oxaliplatin-Induced Tonic-Clonic Seizures Under Anticonvulsant Therapy. [PDF]

Case Rep Oncol Med
Mirzaee M, Azadmehr B, Haji Aghajani S, Jahangard-Rafsanjani Z.   +3 more
europepmc   +1 more source

Correction: Han et al. Enhanced De Novo Lipid Synthesis Mediated by FASN Induces Chemoresistance in Colorectal Cancer. <i>Cancers</i> 2023, <i>15</i>, 562. [PDF]

Cancers (Basel)
Han L, Dai W, Luo W, Ye L, Fang H, Mo S, Li Q, Xu Y, Wang R, Cai G.   +9 more
europepmc   +1 more source

Endothelin-1 Mediates Oxaliplatin Resistance via Activation of YAP Signaling in Colorectal Cancer. [PDF]

Oncol Res
Yang R, Yuan D, Liang C, Zhu S, Huang J, Zhang Y, He W, Li Q, Zhang H.   +8 more
europepmc   +1 more source

Three Versus 6 Months of Adjuvant Oxaliplatin-Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT-An International, Randomized, Phase III, Noninferiority Trial. [PDF]

J Clin Oncol
Iveson T, Saunders MP, Kelly C, Kerr RS, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Boyd KA, Briggs AH, Waterston A, Medley L, Ellis R, Dhadda AS, Harrison M, Falk S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Cunningham D, Hickish T, Gollins S, Wasan HS, Church D, Domingo E.   +31 more
europepmc   +1 more source

A nanocarrier delivery system of oxaliplatin for glioblastoma: synthesis and cytotoxicity of Fe₃O₄@SiO₂/OXA nanocomposites. [PDF]

RSC Adv
Montero Vasquez JM, Gonzalez E, Zapata-Acevedo JF, Pérez DL, Saavedra Gaona IM, Parra Vargas CA, Amaya J, Vargas-Sánchez K, Losada-Barragán M, Rincón Ortiz RJ.   +9 more
europepmc   +1 more source

Tumor Treating Fields (TTFields), and their concomitant application with FOLFOX, are effective for the treatment of gastric cancer cells. [PDF]

Front Oncol
Fishman H, Ene HM, Zeevi E, Flint-Brodsly N, Wainer-Katsir K, Frechtel-Gerzi R, Martinez-Conde A, Greenstein S, Dor-On E, Munster M, Porat Y, Voloshin T, Davidi S, Lavy-Shahaf G, Haber A, Giladi M, Weinberg U, Palti Y.   +17 more
europepmc   +1 more source